Table 2 Clinical and bacteriological outcomes, mortality, and adverse events in both treatment groups after matching
IH + IV polymyxin B (n = 44) | IV polymyxin B (n = 88) | p value | |
|---|---|---|---|
Outcomes | |||
Clinical outcomes | |||
Clinical cure | 19(43.2) | 24(27.3) | 0.066 |
Clinical improvement | 15(34.1) | 27(30.7) | 0.692 |
Clinical failure | 10(22.7) | 35(39.8) | 0.051 |
Recurrence | 0(0.0) | 2(2.3) | 0.552 |
Favorable clinical outcome | 34(77.3) | 51(58.0) | 0.029 |
Unfavorable clinical outcome | 10(22.7) | 37(42.0) | |
Bacteriological outcomes | |||
Eradication | 16(36.4) | 21(23.9) | 0.132 |
Persistence | 18(40.9) | 45(51.1) | 0.267 |
Colonization | 1(2.3) | 12(13.6) | 0.079 |
Recurrence | 9(20.5) | 10(11.4) | 0.161 |
In-hospital mortality | |||
All-cause | 15(34.1) | 37(42.0) | 0.378 |
VAP-related | 12(27.3) | 30(34.1) | 0.428 |
28-day mortality | 7(15.9) | 22(25.0) | 0.234 |
Side effects | |||
AKI | 3(6.8) | 5(5.7) | > 0.999 |
Bronchospasm | 4(9.1) | 0 | – |
Darkening of skin | 44(100) | 88(100) | – |
Facial flushing | 14(31.8) | 25(28.4) | 0.840 |